The objective of this study was to evaluate the antifungal activity of farnesol and its interaction with traditional antifungals against drug-resistant strains of Candida species. To do so, we studied the minimum in vitro inhibitory concentration (MIC) of amphotericin B (AMB), fl uconazole (FLC), itraconazole (ITC), caspofungin (CAS) and farnesol against 45 isolates of Candida spp., i.e., 24 C . albicans , 16 C . parapsilosis and 5 C . tropicalis through the use of the broth microdilution method. Then, the isolates were tested with the combination of farnesol plus drugs to which they were previously found to be resistant. Additionally, the strains were pre-incubated at sub-inhibitory farnesol concentrations and their antifungal susceptibilities were re-evaluated. We found the MIC values for farnesol varied from 4.68 -150 μ M for Candida spp., with 19 isolates having a MIC Ͼ 1 mg/l, 18 a MIC Ն 64 mg/l, 35 having a MIC Ն 1 mg/l and 6 isolates a MIC Ն 2 mg/l or were resistant to AMB, FLC, ITC and CAS, respectively. S ignifi cant MIC reductions were observed when farnesol and antifungal drugs were combined ( P Ͻ 0.05) and when Candida strains were incubated with farnesol ( P Ͻ 0.05). We conclude that the in vitro effects of farnesol improved the activity of traditional antifungals to which the Candida spp. isolates were resistant. These results support further investigation of the role of farnesol in the balance of the sterol biosynthetic pathway and how it interferes with cell viability.
Introduction
The frequency of opportunistic fungal infections caused by Candida species has increased signifi cantly in recent years, especially in HIV-positive patients, organ transplant recipients or those with autoimmune diseases, resulting in high incidence and lethality rates [1, 2] .
antimicrobial potential [8 -10] . Some studies have shown that farnesol increases microbial susceptibility to antibiotics, indicating its possible use as an adjuvant to a presently used therapeutic agent [11] . While it was observed that farnesol has the ability to inhibit the growth of some microorganisms, its mechanism of action has yet to be elucidated [12, 13] . It is believed that it damages the fungal cell membrane by compromising ergosterol synthesis which in turn induces apoptosis in C . albicans through caspase activation [14, 15] . Once activated, caspases cleave the enzyme CCT:phosphocholine cytidylyltransferase-α , causing the disruption of the synthesis of phosphatidylcholine in mammalian cells, but the relevance of this mechanism remains unknown in fungal cells [16] . Thus, the present work aimed at evaluating the effects of farnesol on the antifungal susceptibility of Candida isolates that presented in vitro resistance to amphotericin B, azole derivatives and caspofungin.
Materials and methods

Strain recovery
In this study, 45 isolates of Candida spp. (37 recovered from humans and 8 from animals), belonging to three species (24 C . albicans , 16 C . parapsilosis and 5 C . tropicalis ), were selected on the basis of their resistance to one or more traditional antifungal agents. They were obtained from the culture collection of the Specialized Medical Mycology Center of the Federal University of Cear á , Brazil. The isolates were stored on potato dextrose agar at Ϫ 20 ° C and were streaked on potato dextrose agar for recovery.
After recovery, the identity of all isolates was confi rmed through growth on chromogenic medium (HiCrome Candida Differential Agar -HiMedia Laboratories, India), to assure colony purity, and on cornmeal-tween 80 agar, to observe micromorphological features. Additionally, biochemical assays were performed, such as carbohydrate and nitrogen assimilation and urease production [17, 18] .
Susceptibility testing
Amphotericin B (Sigma Chemical Corporation, USA), fl uconazole (Pfi zer, Brazil), itraconazole (Janssen Pharmaceutica, Belgium), caspofungin (Merck Sharp & Dohme, Brazil) and farnesol (E,E-Farnesol Ն 95% Sigma Chemical Corporation, USA) were employed in these investigations. All were diluted in accord with M27A3 of the Clinical and Laboratory Standards Institute [19] . Farnesol was diluted with 30% dimethyl sulfoxide (DMSO) when used to obtain a stock solution at a concentration of 1,892 μ M. To achieve this, 1.5 ml of farnesol was added to 1.5 ml of 30% DMSO. Afterwards, the farnesol stock solution was diluted with RPMI1640 to a concentration of 600 μ M, in which DMSO was at a concentration of 5%.
The concentration range tested was 0.031 -16 μ g/mL for amphotericin B, itraconazole and caspofungin and 0.125 -64 μ g/mL for fl uconazole [4, 5, 20] . The tested concentrations of farnesol varied from 0.58 -150 μ M [14] . Additionally, the effect of DMSO on the growth of Candida spp. was evaluated by testing different DMSO concentrations without antifungals, ranging from 0.05 -30%. The highest DMSO concentration used in microdilution plates was of 1.25%, which presented no antifungal activity.
Inocula of all Candida spp. were prepared from 2-dayold cultures grown on potato dextrose agar at 35 ° C. Sterile 0.9% saline (5 ml) was added to sterile glass slants and a sample of the colony was introduced to the saline solution, adjusting its concentration to 0.5 on the McFarland scale [19] . Afterwards, the inocula were diluted to 1:100 with RPMI 1640 medium and then to 1:20 with Lglutamine (HiMedia, Mumbai, India), and buffered to pH 7 with 0.165M morpholinepropanesulfonic acid (MOPS). The fi nal concentration of the inocula was 0.5 -2.5 ϫ 10 3 cells/ml.
The minimum inhibitory concentrations (MIC) were determined by the broth microdilution method as described by the Clinical and Laboratory Standards Institute (CLSI) [19] .
Isolates with MICs of Ͼ 1, Ն 64, Ն 1 and Ͼ 2 μ g/mL were considered resistant to amphotericin B, fl uconazole, itraconazole and caspofungin, respectively [19] . For each isolate, drug-free and yeast-free controls were included and all the isolates were tested in duplicate. C . parapsilosis ATCC 22019 and C . krusei ATCC 6258 were included as quality controls for each test performed.
After determining the MICs for each tested drug against all tested isolates, farnesol was combined with the antifungal drugs to which each strain was resistant in order to observe drug interaction [18] and the susceptibility assays were repeated according to CLSI [19] . MIC values for each isolated drug and for farnesol were established as the highest concentration for preparing the combination of drugs. Afterwards, the fractional inhibitory concentration index (FICI) was calculated for each farnesol combination, against all isolates, in order to evaluate drug interaction. The interaction between farnesol and antifungal drugs was considered to be synergistic when FICI Յ 0.5, indifferent at 0.5 Ͻ FICI Ͻ 4, and antagonistic when FICI Ն 4 [21] .
Additionally, in order to evaluate if pre-incubation of the isolates with farnesol affects antifungal resistance, 13 out of 45 of them were randomly selected. These were grown for 24 h at 0.3 g in RPMI 1640 medium containing signifi cance level of 5% was adopted for signifi cant conclusions ( P Ͻ 0.05).
Results
Initially, we determined the MICs for farnesol and each of the antifungal drugs against all 45 Candida spp. isolates. The MICs of farnesol ranged from 4.68 -150 μ M, for all yeast isolates. The MIC values of amphotericin B ranged from 0.0625 -4 mg/L and 19 isolates (7 C . albicans , 11 C . parapsilosis and 1 C . tropicalis ) were resistant (MICs Ͼ 1 mg/l). As for azole derivatives, the MICs of fl uconazole ranged from 0.125 to Ͼ 64 mg/l, with 19 resistant isolates (11 C . albicans , 3 C . parapsilosis and 5 C . tropicalis ; MIC Ͼ 64 mg/l). Concerning itraconazole, the MICs varied from 0.03125 to Ͼ 16 mg/L and 34 strains (20 C . albicans , 9 C . parapsilosis and 5 C . tropicalis ) were resistant to this drug (MIC Ն 1 mg/l). Finally, the caspofungin MICs ranged from 0.0625 to 2 mg/l and 2 C . albicans and 4 C . parapsilosis isolates were found to have higher MIC values (MIC ϭ 2 mg/l; Table 1 ).
We then investigated the combination of farnesol with the drugs to which some strains exhibited in vitro resistance. Overall, farnesol signifi cantly reduced the MICs of all antifungals against all Candida isolates ( P Ͻ 0.05; Table 2 ), without any antagonistic interactions (FICI Ն 4). When combined with farnesol there were signifi cant MIC reductions for all 19 Candida spp. isolates found to be three decreasing consecutive subinhibitory concentrations of farnesol, i.e., MIC/2, MIC/4 and MIC/8. After this period, the isolates were centrifuged for 15 min at 805 g. Inocula from the resulting pellet were prepared in 5 ml of sterile 0.9% saline and antifungal susceptibility assays were repeated with all 13 selected isolates following the methodology described above. The same antifungals were used in this step.
Furthermore, after 24-h-growth in RPMI 1640 supplemented with farnesol, the yeasts were inoculated onto potato dextrose agar and incubated for 48 h. The growth of fungal colonies demonstrated that the cells remained viable after exposure to these sub inhibitory concentrations of farnesol. Additionally, after this period, the antifungal susceptibility tests were repeated against amphotericin B, fl uconazole, itraconazole and caspofungin. (8) 1 (6) 16 (1) 1 (2) 0.25 (5) 150 (2) 2 (6) 32 (2) 2 (5) 0.5 (6) 4 (1) Similarly, the association of fl uconazole and farnesol signifi cantly reduced fl uconazole MICs against the 19 strains that we noted to be resistant to this azole ( P Ͻ 0.05), and synergism (FICI Յ 0.5) was found with all isolates (19/19). The combination of itraconazole and farnesol also reduced MICs of this antifungal against the 34 strains resistant to this drug ( P Ͻ 0.01 for C . albicans and C . parapsilosis and P Ͻ 0.05 for C . tropicalis ). In addition, synergistic interaction (FICI Յ 0.5) was noted against 97.06% of the isolates (33/34). The combination of caspofungin and farnesol reduced MIC values of the former and synergism of the compounds against all of the strains was seen, but statistically signifi cant differences were not observed because of the small number of tested strains ( n ϭ 6). When comparing the MIC reductions for all tested antifungal drugs in association with farnesol, we observed that fl uconazole presented the greatest reduction. Statistical signifi cance was observed when comparing fl uconazole to itraconazole ( P Ͻ 0.05) and amphotericin B ( P Ͻ 0.05) but no statistically signifi cant differences were observed between amphotericin B, itraconazole and caspofungin.
Statistical analysis
When 13 randomly chosen isolates were pre-incubated for 24 h at different farnesol concentrations, there were signifi cant MIC reductions against all tested antifungals ( P Ͻ 0.05). In addition, a concentration-dependent pattern was observed with all antifungals, i.e., exposure to higher sub-inhibitory concentrations of farnesol resulted in signifi cantly higher MIC reductions ( P Ͻ 0.05) (data not shown). The MIC data obtained for the combination of antifungals and farnesol were similar to those obtained after 24-h-incubation at the highest farnesol concentration tested (MIC/2; Table 3 ).
These same 13 isolates that were pre-incubated with farnesol were streaked on potato dextrose agar, incubated for 48 h and their antifungal susceptibility reinvestigated. Growth for 48 h on potato dextrose agar decreased the effects of farnesol on their susceptibility to most antifungals. The MICs were higher for amphotericin B and signifi cantly higher for fl uconazole ( P Ͻ 0.05) and itraconazole ( P Ͻ 0.05), when compared to the values obtained for antifungal-farnesol combinations and pre-incubation at different farnesol concentrations (Table 3) . A concentrationdependent pattern was also observed for all tested antifungal drugs, as previous exposure to higher farnesol 
Discussion
In the present study, we observed that Candida spp. were resistant to at least one of the tested drugs, with 42.2, 37.7 and 75.5% of the isolates being resistant to amphotericin B, fl uconazole and itraconazole, respectively. These data corroborate those previously found by our group concerning the susceptibility profi le of Candida strains [4, 5] . The MIC range observed for farnesol against Candida spp. did not vary among the three tested species, even though it is reported that C . albicans tolerates higher concentrations of this compound when compared to other fungi [22, 23] . In a pioneer study concerning quorum sensing in C . albicans , it was shown that farnesol was not able to alter its growth rate at 30 ° C, using up to 250 μ M of the compound [8] . However, slight differences in this value have been observed by several authors as results seemed to depend on the experimental conditions. Shirtliff et al . showed that 100 μ M of farnesol was able to kill 60% of C. albicans blastoconidia [15] . Weber et al . found that exposure to 100 μ M of farnesol inhibited growth on YNB agar, while this same concentration had little or no effect on Candida growth on YPD agar [24] . Langford et al . reported that farnesol toxicity to C . albicans depended on growth conditions, such as fungal growth phase, incubation temperature and culture medium [22] .
After these studies, farnesol was combined with the antifungal drugs to which some of the isolates were resistant and signifi cant reductions in MIC values were observed for amphotericin B, azole derivatives and caspofungin. In spite of the observed MIC reduction, most of the isolates were within the azole derivatives resistant MIC range established for itraconazole, possibly as the result of the elevated values ( Ն 8 μ g/ml) obtained for this drug before combining it with farnesol. It is important to emphasize that MICs as low as 1 μ g/ml already suggest in vitro resistance. In contrast, the use of farnesol caused all Candida isolates to reach the susceptible MIC range for fl uconazole. With respect to this azole, Jabra-Rizk et al . reported that MIC values of fl uconazole obtained against C. dubliniensis isolates were inversely proportional to farnesol concentrations when it was combined with the antifungal [14] .
A dose-dependent pattern was observed with the preincubation of the 13 Candida spp. isolates at three different sub-inhibitory concentrations of farnesol. There were smaller MICs for all antifungals tested when the strains were incubated at the highest farnesol concentration. For fl uconazole this effect was stronger, considering that Ͼ 64 (2) 2 (1) 0.0625 (1) 2 (1) 1 (1) 1 (1) 2 (3) 0.25 (1) 1 (2) 4 ( Ͼ 64 (1) 4 (2) 1 (1) 1 (1) 0.5 (1) 1 (2) 0.5 (1) 1 (1) 4 (1) 1 (2) 0.03125 (1) 8 (1) 2 (1) 1 (1) 2 (1) 2 (1) Ͼ 64 (1) 8 ( (2) 0.25 (1) 32 (2) 2 (2) 0.03125 (1) 1 (2) 0.5 (2) 0.125 (2) 8 (2) 1 ( pre-incubation with farnesol decreased MICs for this azole, even at the lowest farnesol concentration. These observations suggest that farnesol has an additive effect with traditional antifungal drugs, as evidenced by the reduction in the MIC range for these drugs after incubation with sub-inhibitory concentrations of this compound. Interestingly, the reduction in the MIC range tended to be more discrete when these strains were grown on potato dextrose agar for 48 h after incubation with farnesol. This tendency was more evident when the MICs obtained for fl uconazole before and after growth on potato dextrose agar were compared to those initially found before preincubation with farnesol. It seems that yeast cell damage caused by farnesol is reversible and/or does not preclude these cells from reproducing, which could explain why the MIC values tended to be higher after 48-h growth on potato dextrose agar, indicating that the yeast population had time to recover from farnesol exposure.
Based on these results, it seems that farnesol exerts a stronger effect in association with azole derivatives when compared to the other two classes of drugs, causing a more pronounced reduction in MIC values. This is particularly true for fl uconazole, considering that both combination and pre-incubation with farnesol sharply decreased the MIC values for this drug.
The mechanisms through which farnesol acts on microbial cells still need to be elucidated [9, 22] . It is known that this compound and ergosterol share many precursors in the sterol biosynthetic pathway, including farnesyl-pyrophosphate (FPP), from which C . albicans synthesizes farnesol [10, 25] . It was shown that farnesol production is increased by the presence of drugs that block sterol synthesis in fungi [25, 26] , probably as a consequence of the deviation of the sterol biosynthetic pathway towards farnesol production to avoid the accumulation of toxic intermediate metabolites such as squalene.
Similarly, the exposure to exogenous farnesol may direct the sterol pathway towards ergosterol synthesis, increasing its cellular concentration. Rossignol et al . observed that exposure of C . parapsilosis to farnesol interfered with the expression of genes linked to ergosterol biosynthesis [27] . Six genes were overexpressed, including those involved with the fi nal steps of the pathway, leading to ergosterol production, while three presented reduced expression, including those involved with the synthesis of squalene and squalene epoxide [27] .
Based on the dynamics of the sterol biosynthetic pathway, it seems plausible to suppose that the association of farnesol and azole derivatives leads to the rapid accumulation of the intermediate toxic metabolites of this pathway, considering that both deviation mechanisms are overwhelmed. Besides this, as mentioned before, it can be assumed that exposure to farnesol leads to enhanced production of ergosterol, which in turn may increase fungal susceptibility to amphotericin B. This hypothesis is based on previous reports that reduced ergosterol production is an important mechanism for the development of resistance to this antifungal [28] .
Additionally, we believe that sub-inhibitory doses of caspofungin and farnesol individually do not substantially alter cell viability. However, the combination of these compounds presents a synergistic effect against Candida isolates, possibly because of the deleterious effects on the cell wall and imbalance of the ergosterol biosynthetic pathway caused by caspofungin and farnesol, respectively. This in turn could lead to the accumulation of irreversible alterations and fungal growth inhibition. Curiously, the strains were more susceptible to caspofungin, after 48-hgrowth of the strains on potato dextrose agar, when compared to 24-h pre-incubation at different farnesol concentrations. The reason for this fi nding still needs to be elucidated, but it has been shown that farnesol disrupts cell wall integrity of Aspergillus fumigatus and the fungal ability to respond to wall damages [29] .
Finally, the results obtained in this study, particularly the in vitro effects of farnesol enhancing the activity of traditional antifungals against resistant Candida spp., highlight the need to further investigate the role of farnesol in the balance of the sterol biosynthetic pathway and how it interferes with cell viability.
